Hannah Trisha C. Fuentebella | Ciela Kadeshka A. Fuentes | Pamela Anne M. Gaerlan | Gladys Ericka D. Galang | Rizza Anne Joy P. Galapon | Jouella Camille Q. Mercado | Marra Yoshabel B. Mien | Ma. Allana June C. Miña | Celine Danielle L. Miral | Hannah Faith R. Mojica | Kryle Marxel E. Molina | Rose Ann G. Moncatar | Jose Ronilo G. Juangco
Introduction This study aimed to determine if using Angelica keiskei (ashitaba) tablets as adjuvant therapy to the usual medications for patients with type II diabetes mellitus would result in significant lowering of blood sugar. Methods The antidiabetic effect of Angelica keiskei was evaluated in diabetic Filipino patients as an adjuvant treatment to antidiabetic medications through a randomized single-blind placebo-controlled clinical trial. Patients recruited from select barangays in Quezon City and San Juan City were randomly assigned to either ashitaba or placebo group. The effect was measured by obtaining and comparing fasting blood sugar pre- and post-treatment. Results There was no significant change in FBS from the baseline in the ashitaba (p = 0.174) and placebo (p = 0.128) groups after two weeks. There was a significant increase in the systolic BP of the ashitaba group (p= 0.014) but not in the placebo group. There were no significant changes in the diastolic BP of either group. Conclusion Dietary supplementation of 500 mg ashitaba capsules thrice daily for two weeks did not exhibit any glucose-lowering effects among type II diabetic patients maintained on oral anti-diabetic medications.
1. Wild S, Roglic G, Green A, Sicree R, King G. Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diab Care [Internet] 2004 May; 27(5): 1047–53. Available from: https://www.ncbi.nlm.nih.gov/pubmed/15111519
2. Ramachandran A, Ma RC, Snehalatha C. Diabetes in Asia. Lancet [Internet] 2010; 375: 408-18. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19875164.
3. Soria MLB, Sy RG, Vega BS, et al. The incidence of type 2 diabetes mellitus in the Philippines: A 9-year cohort study. Diabetes Res Clin Pract [Internet]. Published online: September 22, 2009
4. Epidemiology Bureau Department of Health. 2016 Philippine Health Statistics Update [Internet]. 2016 [cited 2017 Nov 5]
5. Sarkar SD, Nahar L. Natural medicine: the genus Angelica. Curr Med Chem [Internet] 2004 [cited 2017 Nov 4]; 11(11): 1479-500. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15180579
6. Ohnogi H, Enoki T, Hayami S, Kudo Y. Antidiabetic effect and safety of long-term ingestion of “ashitaba” (Angelica keiskei) powder containing chalcone (4HD) on borderline mild hyperglycemia. Jpn Pharmacol Ther [Internet] 2007 [cited 2017 Nov 7]; 35(6): 647-60. Available from: http://www.lifescience.co.jp/yk/yk07/jun/ab9.htm
7. Enoki T, Ohnogi H, Nagamine K, et al. Antidiabetic activities of chalcones isolated from a Japanese Herb, Angelica keiskei. J Agric Food Chem [Internet] 2007 July [cited 2017 Nov 8]; 55(15): 6013-7. Available from: https://www.ncbi.nlm.nih.gov/pubmed/17583349
8. 2017 National Ethical Guidelines for Health and Health-Related Research [Internet]. Philippine Health Research Ethics Board, Department of Science and Technology-Philippine Council for Health Research and Development. 2017 Aug [cited 2017 Nov 7].
9. Ohnogi H, Hayami S, Kudo Y, Enoki T. Efficacy and safety of ashitaba (Angelica keiskei) on the patients and candidates with metabolic syndrome: A pilot study. JJCAM [Internet]. 2012 March [cited Nov 8]; 9(1); 49-55. Available from: https://www.jstage.jst.go.jp/article/jcam/9/1/9_1_49/_pdf
10. Mus LM, Denecker G, Speleman F, Roman BI. Vehicle development, pharmacokinetics and toxicity of the anti- invasive agent 4-fluoro-3’,4’,5’-trimethoxychalcone in rodents. [Internet] PLoS One. 2018 Feb; 13(2). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823406
11. Caesar LK, Cech NB. A Review of the medicinal uses and pharmacology of ashitaba. Planta Med [Internet] 2016 Sep [cited 2017 Nov 8]; 82(14): 1236-45
ISSN 2244-4378 (Print)
Philippine E-Journals
